Log in using OpenID

Glioblastoma Multiforme Treatment (GBM) Market

Glioblastoma Multiforme Treatment (GBM) Market US$0.91 bn in 2022,
A new report published by Transparency Market Research on the global glioblastoma treatment
market provides insights into the growth drivers, potential restraints, and growth opportunities that
the market is likely to witness between 2014 and 2022. The report is titled “Glioblastoma
Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast 2014 - 2022” and is available for sale in the company website. The market, according to
the report, will grow from a valuation of US 0.34 bn in 2013 to US$0.91 bn in 2022, exhibiting a
positive CAGR of 11.40% during the period.
Read Report overview @
Glioblastoma multiforme (GBM) is the most lethal and common brain tumor in adults. The
treatment modalities available in the market at present include surgical resection, followed by
radiotherapy and chemotherapy. Despite being around in the healthcare industry since the last few
years, these modalities have done little to decrease the overall mortality rate in patients. Recurrence
of disease, glioma stem cell resistance to conventional modalities, and invasiveness of GBM are a
few factors hampering the success rate of available treatment methods.
Novel treatment strategies are, therefore, desperately required to address such unmet medical needs,
and the GBM pipeline already includes a mix of small molecules, immunotherapy, biological, and
other types of therapeutics. Advances introduced in gene technology and molecular biology also
provide lucrative novel possibilities for efficient treatment of patients diagnosed with GBM. The
report discusses the aforementioned factors in detail as the most crucial growth drivers of the
glioblastoma treatment market.
Some of the glioblastoma treatments approved by the FDA include bevacozumab, temozolomide,
and carmustine. Of these, carmustine, known by the brand name Gliadel (a product of Arbor
Pharmaceuticals, LLC), is surgical implant. Likewise, bevacozumab, brand named Avastin by
Genetech/Roche, is used for intravenous therapy and temozolomide (brand named
Temodal/Temodar/Temcad) is primarily recommended for oral or intravenous chemotherapy. The
report analyzes the market dynamics of these available drugs and therapies. It also studies their
effectiveness in glioblastoma treatment to measure the scope for novel therapies.
According to the report, rising awareness regarding the types of brain tumors, increased funding for
R&D in drug delivery technologies, and the introduction of modern diagnostic techniques fuel the
market for glioblastoma treatment. Among the available modalities, in 2013, the glioblastoma
treatment market was dominated by temozolomide. However, the drug recently lost its patent,
allowing generic drugs to foray into the market and significantly bring down the market share of
Request Sample [email protected]
Among the regional markets for glioblastoma treatment, North America occupied the leading
position due to the high incidence of glioblastoma multiforme in the region. The presence of an
increasing number of associations, such as the National Brain Tumor Society, the American Brain
Tumor Association, the Brain Tumor Foundation of Canada, and others, that are engaged in
boosting the awareness regarding GBM across the region is aiding the growth of the North America
glioblastoma treatment market.
Moreover, most prominent GBM drug manufacturers are located in the region, which further fuels
the glioblastoma treatment market in North America. Asia Pacific, according to the report, will
emerge as the most lucrative market for glioblastoma treatment drugs in the coming years. Rising
awareness regarding GBM and rapid development of the healthcare infrastructure in several
countries in Asia Pacific is propelling the glioblastoma treatment market in the region.
vakhas298   documents Email
Business and Leadership
File Size
34 KB
Report inappropriate content